Similarly, research by Menyhárt et al. revealed that EPB41L2, one of four genes (alongside HLA-DQB1, LTF, and SFRP1), is consistently overexpressed in tumor samples from ovarian cancer patients with disease progression after topotecan therapy (39). The gene discussed is LTF; the disease is neoplasm.